Status:
TERMINATED
Endothelial Function and Autonomic Regulation After Short-term Smoking Cessation: Varenicline Versus Placebo
Lead Sponsor:
Mayo Clinic
Conditions:
Smoking
Eligibility:
MALE
18-40 years
Phase:
NA
Brief Summary
The purpose of this study is to evaluate endothelial function and autonomic regulation (for example, heart rate and blood pressure) in smokers before and after short-term smoking cessation. The endoth...
Detailed Description
Smoking is a major cardiovascular risk factor and is associated with arterial endothelial dysfunction, a key event in atherosclerosis. Previous observations have suggested that smoking-related endothe...
Eligibility Criteria
Inclusion
- Regular smokers (currently \>10 cigarettes/day; \>5 pack years)
- Willing to quit smoking for at least the duration of the study
- Able and willing to give written informed consent
Exclusion
- Known condition causing endothelial dysfunction except smoking (i.e. diabetes, hyperlipi¬demia, arterial hypertension, obesity)
- Regular drug treatment and/or sporadic consumption of drugs within the last 4 weeks (exclusion has to be decided in each individual)
- Acute or chronic illness
- Participation in clinical trial within 1 month before the study
- Excessive daily intake of alcohol (\>2 servings per day) or caffeine (\>4 servings/day)
- Drug and/or alcohol abuse.
Key Trial Info
Start Date :
March 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2010
Estimated Enrollment :
19 Patients enrolled
Trial Details
Trial ID
NCT00673595
Start Date
March 1 2007
End Date
February 1 2010
Last Update
March 16 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic
Rochester, Minnesota, United States, 55905